What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Multiple myeloma
His primary areas of investigation include Multiple myeloma, Internal medicine, Surgery, Bortezomib and Oncology.
Maria-Victoria Mateos works in the field of Multiple myeloma, namely Melphalan.
His research on Internal medicine often connects related areas such as Gastroenterology.
His Surgery study incorporates themes from Adverse effect and Urology.
Maria-Victoria Mateos combines subjects such as Thalidomide and Median follow-up with his study of Bortezomib.
The study incorporates disciplines such as Elotuzumab and Daratumumab in addition to Oncology.
His most cited work include:
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. (1547 citations)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Multiple myeloma, Internal medicine, Oncology, Bortezomib and Lenalidomide.
His Multiple myeloma study combines topics from a wide range of disciplines, such as Clinical trial and Minimal residual disease.
His Internal medicine research incorporates themes from Gastroenterology and Surgery.
Maria-Victoria Mateos has researched Gastroenterology in several fields, including Progressive disease and Neutropenia.
In his study, which falls under the umbrella issue of Oncology, Open label is strongly linked to Refractory Multiple Myeloma.
The concepts of his Bortezomib study are interwoven with issues in Proteasome inhibitor, Urology, Adverse effect, Pharmacology and Hazard ratio.
He most often published in these fields:
- Multiple myeloma (72.64%)
- Internal medicine (70.83%)
- Oncology (41.49%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (70.83%)
- Multiple myeloma (72.64%)
- Oncology (41.49%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Daratumumab.
While the research belongs to areas of Internal medicine, Maria-Victoria Mateos spends his time largely on the problem of Gastroenterology, intersecting his research to questions surrounding Dosing.
His Multiple myeloma research is multidisciplinary, incorporating elements of Adverse effect, Disease and Refractory.
His Oncology research includes elements of Newly diagnosed, Clinical trial, Subgroup analysis and Minimal residual disease.
His biological study spans a wide range of topics, including Cancer research and Cyclophosphamide.
His research investigates the connection between Daratumumab and topics such as Randomized controlled trial that intersect with problems in Regimen.
Between 2019 and 2021, his most popular works were:
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial (93 citations)
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. (62 citations)
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. (53 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Maria-Victoria Mateos focuses on Multiple myeloma, Internal medicine, Dexamethasone, Oncology and Daratumumab.
His Multiple myeloma research is multidisciplinary, incorporating perspectives in Clinical trial, Disease and Transplantation.
His Internal medicine study typically links adjacent topics like Gastroenterology.
His Dexamethasone research incorporates elements of Cancer research and Bortezomib.
His Bortezomib research is multidisciplinary, relying on both Melphalan and Intensive care medicine.
His work carried out in the field of Oncology brings together such families of science as Venetoclax and Flow cytometry.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
